Dimension Therapeutics, Inc. Securities Litigation
On or around 12/11/2017 (Notice of voluntarily dismissal)
Filing Date: October 11, 2017
This action stems from a proposed transaction announced on October 3, 2017 (the “Proposed Transaction”), pursuant to which Dimension Therapeutics, Inc. (“Dimension” or the “Company”) will be acquired by Ultragenyx Pharmaceutical Inc. (“Parent”) and Mystic River Merger Sub Inc. (“Merger Sub” and together with Parent, “Ultragenyx”) through a tender offer currently set to expire on November 6, 2017 (the “Tender Offer”).
On October 2, 2017, Dimension’s Board of Directors (the “Board” or “Individual Defendants”) caused the Company to enter into an agreement and plan of merger (the “Merger Agreement”) with Ultragenyx. Pursuant to the terms of the Merger Agreement, shareholders of Dimension will receive $6.00 per share in cash. On October 10, 2017, defendants filed a Solicitation/Recommendation Statement (the “Solicitation Statement”) with the United States Securities and Exchange Commission (“SEC”) in connection with the Proposed Transaction.
The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.
This case was voluntarily dismissed on December 11, 2017.
Company & Securities Information
Defendant: Dimension Therapeutics, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: DMTX
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Louis Scarantino, et al. v. Dimension Therapeutics, Inc., et al.
COURT: D. Massachusetts
DOCKET #: 17-CV-11964
JUDGE: Hon. Mark L. Wolf
DATE FILED: 10/11/2017
CLASS PERIOD START: 10/03/2017
CLASS PERIOD END: 10/11/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Matorin Law Office, LLC 18 Grove Street, Suite 5, Matorin Law Office, LLC, MA 02482 (781) 453-0100 ·